Biotechnology companies in Pennsylvania are at the forefront of medical innovation, focusing on areas such as gene therapy, drug development, and regenerative medicine. These companies not only research and manufacture new therapies but also partner with academic institutions to harness local talent. The sector is rapidly evolving, especially with advancements in personalized medicine and the increasing demand for biologic drugs. As therapeutic techniques gain sophistication, firms are pivoting to include technologies that promise enhanced efficacy and safety for patients. Pennsylvania is poised for growth, fuelled by an impressively skilled workforce and cutting-edge research facilities.

The companies listed here showcase a mix of sizes and specializations, centered primarily in Philadelphia and Pittsburgh. While many were founded in the last decade, some date back to the 1960s. Their focuses range from gene therapies, like Spark Therapeutics and Castle Creek Biosciences, to therapeutic antibodies, such as Integral Molecular. With employee counts varying from small teams to several hundred, this group exemplifies an exciting blend of innovation and practical applications that address pressing healthcare needs in Pennsylvania and beyond.

Read on to explore the notable biotechnology companies in Pennsylvania.

Top 23 Biotechnology Companies in Pennsylvania

1. Spark Therapeutics, Inc.

• Website: sparktx.com
• Ownership type: Corporate
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $4.3B, February 2019
• Founded year: 2013
• Headcount: 501-1000
• LinkedIn: spark-therapeutics-inc

Spark Therapeutics, Inc., founded in 2013 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to developing gene therapy treatments for genetic diseases. Their focus includes conditions such as hemophilia and inherited retinal diseases, where they aim to provide innovative, long-lasting therapies that can transform patient care. Spark operates a fully integrated model that combines research, development, and manufacturing of gene therapies. The company has made significant strides in the field, including the launch of Luxturna, the first approved gene therapy for a genetic disease in both the U.S. and EU. With a workforce of approximately 847 employees, Spark is committed to advancing healthcare through its proprietary adeno-associated viral (AAV) gene therapy platform. Their recent investment in a new Gene Therapy Innovation Center underscores their ambition to enhance gene therapy manufacturing capabilities and foster collaboration within the scientific community.

2. Integral Molecular

• Website: integralmolecular.com
• Ownership type: Private
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $8.0M, October 2024
• Founded year: 2001
• Headcount: 51-200
• LinkedIn: integral-molecular

Integral Molecular, founded in 2001 and based in Philadelphia, Pennsylvania, is a biotechnology company that focuses on innovative technologies and therapeutic antibodies for membrane protein targets. The company has carved out a niche in the industry by providing services such as antibody discovery and virology reagents, which assist pharmaceutical and biotech firms in developing effective therapies and vaccines. Integral Molecular's expertise in membrane proteins, which are involved in a significant portion of drug targets, positions them as a key player in the biotechnology field. They have collaborated with over 100 top biotech and pharmaceutical companies, showcasing their impact and reach within the industry. Recently, they secured $8 million in funding through a grant, indicating ongoing support for their research initiatives. Integral Molecular continues to advance its therapeutic pipeline and has achieved ISO 9001 certification for its quality management systems, reflecting its commitment to excellence in service delivery.

3. Center for Breakthrough Medicines

• Website: breakthroughmedicines.com
• Ownership type: Corporate
• Headquarters: King Of Prussia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: September 2023
• Founded year: 2020
• Headcount: 201-500
• LinkedIn: center-for-breakthrough-medicines

Center for Breakthrough Medicines (CBM) is a biotechnology company based in King of Prussia, Pennsylvania, established in 2020. The company specializes in the development and manufacturing of advanced therapies, focusing on viral vector and cell therapy manufacturing. CBM offers a comprehensive suite of services that includes process development, analytical testing, plasmid DNA manufacturing, and quality and regulatory support. Their mission is to save lives by accelerating the development of advanced therapies, and they work closely with pharmaceutical and biotechnology clients to bring innovative treatments to market. CBM has built a reputation for its commitment to quality and efficiency, aiming to transform the landscape of advanced therapies through its integrated capabilities and experienced team.

4. SK Life Science Labs

• Website: sklslabs.com
• Ownership type: Private
• Headquarters: King Of Prussia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: proteovant-therapeutics

SK Life Science Labs, based in King of Prussia, Pennsylvania, is a biotechnology company that specializes in drug discovery and development. Founded in 2021, the company is dedicated to creating innovative therapies for oncology and immunology. They leverage proprietary platforms, including targeted protein degradation and the MOPED™ molecular glue platform, to develop transformative medicines. Their clientele includes pharmaceutical companies and research institutions seeking advanced treatment solutions. As a subsidiary of SK Biopharmaceuticals, SK Life Science Labs benefits from the backing of a significant global conglomerate, enhancing their capabilities in research and development. The company is committed to improving patient outcomes through their focused pipeline, which includes multiple programs targeting various cancers and immunological disorders.

5. Castle Creek Biosciences, Inc.

• Website: castlecreekbio.com
• Ownership type: Venture Capital
• Headquarters: Exton, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $75.0M, February 2025
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: castlecreekbio

Castle Creek Biosciences, Inc. is a biotechnology firm based in Exton, Pennsylvania, established in 2020. The company is dedicated to developing innovative gene therapies aimed at treating genetic diseases, with a particular focus on dystrophic epidermolysis bullosa (DEB). This condition is a severe genetic disorder that leads to fragile skin and significant morbidity. Castle Creek is advancing its lead candidate, D-Fi, which is designed to provide functional type VII collagen to affected areas, addressing the underlying cause of DEB. The company has its own in-house manufacturing capabilities, allowing for the production of its therapies under current good manufacturing practices (cGMP). This control over manufacturing is essential for ensuring the quality and availability of their investigational products. Recently, Castle Creek secured $75 million in funding, which will support its clinical trials and further development of its therapies. The company is committed to improving the lives of patients and families facing limited treatment options for genetic diseases.

6. Tavotek Biotherapeutics

• Website: tavotek.com
• Ownership type: Corporate
• Headquarters: Lower Gwynedd Township, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 68%, China 32%
• Latest funding: Series B, $35.0M, November 2021
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: tavotek

Tavotek Biotherapeutics, based in Lower Gwynedd Township, Pennsylvania, is a biopharmaceutical company that specializes in the discovery, development, and commercialization of therapeutic medicines aimed at addressing significant unmet medical needs. Founded in 2019, Tavotek is focused on serious diseases, particularly cancer and autoimmune conditions. The company operates through advanced research platforms, including TavoSelect™, TavoPrecise™, and TavoELITE™, which facilitate the development of biologics targeting complex disease mechanisms. Tavotek's pipeline includes multiple candidates in various stages of development, with a strong emphasis on innovative therapies that can improve patient outcomes. The company has also established a global presence, with operations in both the United States and China. In November 2021, Tavotek raised $35 million in a Series B funding round, further bolstering its research capabilities and clinical development initiatives.

7. BlueWhale Bio

• Website: bluewhale.bio
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $18.0M, September 2023
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: bluewhale-bio

BlueWhale Bio, Inc. is a biotechnology firm based in Philadelphia, Pennsylvania, established in 2022. The company is dedicated to enhancing cell-based and gene therapies, focusing on improving manufacturing processes to increase patient access and treatment outcomes. With a team led by renowned immunotherapy experts Carl June and James Riley from the University of Pennsylvania, BlueWhale Bio is positioned to develop groundbreaking products that could transform the current treatment paradigm. The company has recently raised $18 million in seed funding, indicating strong investor confidence in its potential. BlueWhale Bio aims to make cell therapy products more accessible and effective, addressing the growing demand in the healthcare sector.

8. Enterin Inc.

• Website: enterininc.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $5.1M, December 2023
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: enterin-inc.

Enterin Inc. is a biotechnology firm based in Philadelphia, Pennsylvania, founded in 2016. The company is dedicated to developing innovative therapies for neurodegenerative diseases, with a particular focus on Parkinson's Disease. Their lead drug, ENT-01, aims to repair the gut-brain axis, a critical pathway believed to influence various neurological conditions. Enterin is currently conducting clinical trials, including the KARMET Phase 2b and RASMET Phase 2a studies, to evaluate the efficacy of ENT-01. The company has recently secured funding of approximately $5 million in December 2023, reflecting investor confidence in their research and development efforts. Enterin's work is significant for patients seeking improved quality of life through novel therapeutic approaches.

9. Rockland Immunochemicals, Inc.

• Website: rockland.com
• Ownership type: Corporate
• Headquarters: Limerick Township, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 97%, Germany 3%
• Latest funding: March 2010
• Founded year: 1962
• Headcount: 51-200
• LinkedIn: rockland-immunochemicals-inc-

Rockland Immunochemicals, Inc. is a biotechnology company based in Limerick Township, Pennsylvania, established in 1962. The company specializes in producing high-quality antibodies, reagents, and related services tailored for research purposes. Rockland serves a wide array of clients in the life sciences, biopharma, and diagnostics sectors, providing custom solutions that cater to the specific needs of researchers and scientists. Their product line includes monoclonal and polyclonal antibodies, blood products, proteins, peptides, and various reagents essential for laboratory work. Additionally, Rockland offers custom antibody production and analytical tools for RNA therapeutics, showcasing their adaptability to emerging scientific needs. The company has built a reputation for excellence through its attention to detail and superior customer service, which has fueled scientific advances for over two generations.

10. Aro Biotherapeutics

• Website: arobiotx.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 96%, Bangladesh 4%
• Latest funding: Series B, $41.5M, November 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: aro-biotherapeutics

Aro Biotherapeutics, based in Philadelphia, Pennsylvania, is a biotechnology firm that specializes in the development of targeted genetic medicines. The company leverages its proprietary Centyrin platform to create innovative therapeutic candidates aimed at treating complex diseases. Aro's approach involves the selective modulation of gene targets in disease tissues, which is designed to enhance both efficacy and safety. Their pipeline includes Centyrin-based therapeutic candidates, and they are actively engaged in partnerships with healthcare providers and pharmaceutical companies. Aro has recently secured $41.5 million in Series B funding, which underscores their commitment to advancing genetic therapies and addressing previously challenging medical conditions. With a dedicated team and a clear focus on oligonucleotide-based therapeutics, Aro is positioned to make a significant impact in the biotechnology industry.

11. Exegenesis Bio

• Website: exegenesisbio.com
• Ownership type: Private Equity
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: China 65%, United States (USA) 35%
• Latest funding: Series B, February 2021
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: exegenesis

Exegenesis Bio is a biotechnology company based in Philadelphia, Pennsylvania, specializing in gene and cell therapies. Founded in 2019, the company has developed a strong focus on creating innovative genetic medicines aimed at treating serious conditions such as Spinal Muscular Atrophy, Parkinson's Disease, and Wet Age-related Macular Degeneration. With a commitment to research and development, Exegenesis Bio is advancing an early to clinical-stage pipeline that includes several promising therapies. The company operates globally, with offices in the United States, China, and Singapore, and has built integrated manufacturing capabilities to support its operations. Exegenesis Bio has raised over $120 million in funding, which has facilitated its growth and expansion in the biotechnology sector. Their mission is to increase access to gene and cell therapies for patients worldwide, reflecting a patient-centered approach in their operations.

12. Rockland Immunochemicals, Inc.

• Website: rockland-inc.com
• Ownership type: Private
• Headquarters: Limerick Township, Pennsylvania, United States (USA)
• Founded year: 1962
• Headcount: 51-200
• LinkedIn: rockland-immunochemicals-inc-

Rockland Immunochemicals, Inc. is a biotechnology company based in Limerick Township, Pennsylvania, specializing in the production of high-quality antibodies, blood products, and related services tailored for researchers in the life sciences sector. Established in 1962, the company has built a reputation for excellence in providing essential tools for research and diagnostics across various industries, including AgBio and Biopharma. Rockland offers a wide range of products, such as primary and secondary antibodies, proteins, peptides, and custom antibody production services. Their commitment to quality is evident in their rigorous manufacturing processes and the sourcing of blood products from healthy, monitored donors. Rockland's services extend to protein and antibody characterization, assay development, and cell culture services, showcasing their comprehensive approach to supporting scientific research. The company continues to play a significant role in advancing life science research, making it a relevant player in the biotechnology industry.

13. Interius BioTherapeutics

• Website: interiusbio.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $51.4M, June 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: interius-biotherapeutics

Interius BioTherapeutics, based in Philadelphia, Pennsylvania, is a biotechnology firm that specializes in the development of innovative gene therapies. Founded in 2019, the company is focused on in vivo cell-specific gene delivery technologies, particularly for creating CAR T cells aimed at treating hematologic malignancies. Their unique approach allows for the generation of CAR T cells directly within the patient's body, eliminating the need for ex vivo cell manipulations and the associated risks of pre-conditioning chemotherapy. Interius has made significant progress in its clinical development, recently receiving Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance from the Australian Therapeutic Goods Administration (TGA) to commence a Phase 1 clinical trial for its lead candidate, INT2104. This investigational therapy targets B cell malignancies and represents a novel off-the-shelf treatment option. The company has also secured substantial funding, with a recent Series B round raising over $51 million, which underscores its potential in the biotechnology sector. Interius is committed to advancing gene therapy and has established partnerships to enhance its manufacturing capabilities, further solidifying its position in the industry.

14. Evrys Bio

• Website: evrysbio.com
• Ownership type: Private
• Headquarters: Doylestown, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $34.3M, July 2021
• Founded year: 2012
• Headcount: 1-10
• LinkedIn: forge-life-science

Evrys Bio, founded in 2012 and based in Doylestown, Pennsylvania, is a private biotechnology company dedicated to the development of innovative antiviral therapies. The company specializes in targeting human proteins known as sirtuins to create broad-spectrum antivirals that can effectively combat various viral infections. Their approach is distinct from traditional antiviral drugs, which typically target a single virus. Instead, Evrys Bio's products aim to enhance the body's intrinsic immunity, potentially transforming the treatment landscape for viral diseases. The company has four active drug discovery programs, including treatments for respiratory infections and hepatitis, and has received $34.3 million in funding as of July 2021, underscoring its commitment to addressing significant clinical challenges in the antiviral space.

15. Third Arc Bio

• Website: thirdarcbio.com
• Ownership type: Private Equity
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $165.0M, July 2024
• Founded year: 2022
• Headcount: 11-50
• LinkedIn: third-arc-bio

Third Arc Bio, based in Philadelphia, Pennsylvania, is a biotechnology company founded in 2022. The firm is dedicated to developing transformational therapies aimed at treating solid tumors and inflammatory diseases. Their innovative approach centers on multifunctional antibodies designed to create immune synapses, which are crucial for precisely activating or inhibiting T cells. This technology has the potential to redefine treatment standards in oncology and immunology. The company has attracted significant attention in the industry, evidenced by their recent $165 million Series A funding round completed in July 2024. With a team of experienced professionals, including CEO Peter F. Lebowitz, MD, PhD, and CSO Sanjaya Singh, PhD, Third Arc Bio is well-positioned to advance its mission of delivering superior biologics to healthcare providers and pharmaceutical companies.

16. KaliVir Immunotherapeutics

• Website: kalivir.com
• Ownership type: Venture Capital
• Headquarters: Pittsburgh, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, March 2022
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: kalivir-immunotherapeutics

KaliVir Immunotherapeutics, based in Pittsburgh, Pennsylvania, is a biotechnology firm that specializes in oncolytic viral immunotherapy aimed at treating cancer. Founded in 2019, the company is dedicated to developing innovative therapies, particularly its lead candidate VET3-TGI, which targets advanced solid tumors. KaliVir's approach leverages the unique properties of oncolytic viruses to enhance immune responses against cancer cells. The company is actively involved in clinical trials, recently announcing the dosing of its first patient in a Phase 1/1b trial for VET3-TGI. With a team of experienced professionals in the biotechnology field, KaliVir is positioned to contribute to advancements in cancer treatment through its research and development efforts.

17. Spirovant Sciences, Inc.

• Website: spirovant.com
• Ownership type: Private
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $4.5M, January 2019
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: spirovant

Spirovant Sciences, Inc., based in Philadelphia, Pennsylvania, is a biotechnology firm founded in 2016. The company specializes in gene therapy aimed at treating respiratory diseases, particularly cystic fibrosis. Utilizing a proprietary Adeno-Associated Virus (AAV) platform, Spirovant is developing innovative treatments designed to restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in patients. Their lead program, SP-101, is currently in clinical development and has garnered attention for its potential to provide a mutation-agnostic solution for cystic fibrosis patients who do not respond to existing therapies. Spirovant has received significant support from the Cystic Fibrosis Foundation and has been recognized for its scientific contributions. The company secured $4.5 million in funding through a grant in January 2019, which underscores its commitment to advancing gene therapy solutions. With a dedicated team of experienced professionals, Spirovant is positioned to make a meaningful impact in the field of respiratory disease treatment.

18. Fairmount Funds Management LLC

• Website: fairmountfunds.com
• Ownership type: Private
• Headquarters: Conshohocken, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: fairmount-funds-management-llc

Fairmount Funds Management LLC, based in Conshohocken, Pennsylvania, is an investment firm established in 2016. The company specializes in the biotechnology and life sciences sectors, focusing on providing capital to emerging therapies developed by biotech firms. By investing in these promising new therapies, Fairmount helps biotech companies secure the necessary funding to advance their innovative solutions. With a team of 28 employees, Fairmount is dedicated to identifying and supporting the next wave of breakthroughs in healthcare, making them a significant player in the investment landscape of the biotechnology industry.

19. VintaBio

• Website: vintabio.com
• Ownership type: Venture Capital
• Headquarters: Philadelphia, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $64.0M, April 2023
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: vinta-bio

VintaBio, founded in 2020 and based in Philadelphia, Pennsylvania, is a biotechnology company dedicated to advancing gene therapy through the development and production of adeno-associated viral (AAV) vectors. The company offers a range of services, including research vector production, process development, and regulatory support, aimed at facilitating the transition of gene therapies from discovery to clinical application. With a team boasting over 120 years of combined experience in the cell and gene therapy field, VintaBio is well-equipped to support various gene therapy programs. Their proprietary platform is designed to produce high-quality vectors efficiently, ensuring that cost does not hinder the development of innovative treatments. In April 2023, VintaBio secured $64 million in funding, reflecting investor confidence in their mission to provide accessible gene therapy solutions. This financial support will likely enhance their capabilities and expand their impact in the biotechnology sector.

20. Kibow Biotech, Inc.

• Website: kibowbiotech.com
• Ownership type: Private
• Headquarters: Newtown Square, Pennsylvania, United States (USA)
• Founded year: 1997
• Headcount: 11-50
• LinkedIn: kibow-biotech-inc

Kibow Biotech, Inc., based in Newtown Square, Pennsylvania, is a biotechnology company founded in 1997. The firm specializes in the development and commercialization of scientifically formulated probiotic and prebiotic dietary supplements. Their primary focus is on products that support kidney health and boost immune function, particularly for the geriatric population. Kibow Biotech is dedicated to addressing health challenges associated with kidney disease and other related conditions through innovative dietary solutions. The company operates under strict quality standards, ensuring that their products are manufactured in compliance with Good Manufacturing Practices (cGMP). They have invested significantly in research and development, conducting clinical trials to validate the efficacy of their products. Kibow Biotech's product line includes Renadyl™, Biomunity™, Kibow® Cardio, and Kibow Fortis™, each designed to meet specific health needs. Their commitment to quality and scientific backing positions them as a relevant entity in the biotechnology sector, particularly in the health supplement niche.

21. Fox Chase Therapeutics Discovery, Inc.

• Website: fctdi.com
• Ownership type: Private
• Headquarters: Doylestown, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2008
• Headcount: 11-50
• LinkedIn: fox-chase-chemical-diversity-center-inc.

Fox Chase Therapeutics Discovery, Inc. (FCTDI), based in Doylestown, Pennsylvania, is a biotechnology company established in 2008. The firm specializes in drug discovery and development, focusing on the early stages of research to create new therapeutic candidates. FCTDI collaborates with pharmacologists and medical doctors, leveraging their expertise in medicinal chemistry and access to a substantial collection of over 34,000 reagents. This resource allows them to expedite the lead optimization process, enhancing their ability to translate innovative ideas into potential treatments. FCTDI has successfully advanced three drug candidates into clinical trials, showcasing their effectiveness in the biotechnology field. Their partnerships with institutions like The Wistar Institute and Oligomerix, Inc. highlight their commitment to collaborative research aimed at addressing significant health challenges, including Alzheimer's disease and various cancers.

22. Imagine Pharma

• Website: imaginepharma.com
• Ownership type: Venture Capital
• Headquarters: Pittsburgh, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $10.0M, October 2023
• Founded year: 2016
• Headcount: 1-10
• LinkedIn: imagine-pharmaceuticals

Imagine Pharma, based in Pittsburgh, Pennsylvania, is a biotechnology company founded in 2016. The firm is dedicated to developing innovative therapies and drug delivery systems, with a particular emphasis on the oral delivery of biologics and regenerative medicine. Their research targets critical health conditions, including diabetes and wound healing, aiming to provide advanced treatment options for patients. Imagine Pharma operates through a robust research and development framework, which is essential for addressing unmet medical needs in the healthcare sector. The company has recently secured $10 million in Series A funding as of October 2023, which underscores its active role in the biotechnology industry and its commitment to advancing its therapeutic programs. With a small team of around 19 employees, Imagine Pharma is positioned to make significant contributions to the field of biotechnology, particularly through its innovative approaches to drug delivery and regenerative therapies.

23. Avista Therapeutics

• Website: avistatx.com
• Ownership type: Corporate
• Headquarters: Pittsburgh, Pennsylvania, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: June 2015
• Founded year: 2021
• Headcount: 11-50
• LinkedIn: avista-therapeutics

Avista Therapeutics, based in Pittsburgh, Pennsylvania, is a biotechnology company founded in 2021. The company is dedicated to developing innovative gene therapies aimed at treating retinal diseases, including rare ophthalmic conditions that significantly affect patients' quality of life. Utilizing their proprietary scAAVengr platform, Avista generates and validates a toolkit of adeno-associated virus (AAV) vectors designed for targeted gene delivery to specific retinal cell types. This approach allows for minimally invasive treatment options, enhancing accessibility for patients. Avista has formed a strategic partnership with Roche, which involves the development of novel AAV gene therapy vectors, further solidifying its position in the biotechnology industry. The company is staffed by a team of experts in clinical ophthalmology and viral vector technology, reflecting a strong foundation for future advancements in gene therapy.

Biotechnology Insights: Key Companies in Pennsylvania

Want to Find More Biotechnology Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!